Your browser doesn't support javascript.
loading
Availability of Genetic Tests in Public Health Services in Brazil: Data from the Brazilian Rare Diseases Network.
de Oliveira, Bibiana Mello; Neiva, Mariane Barros; Carvalho, Isabelle; Schwartz, Ida Vanessa Doederlein; Alves, Domingos; Felix, Temis Maria.
Afiliação
  • de Oliveira BM; Medical Genetics Service, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.
  • Neiva MB; Postgraduation Program in Genetics and Molecular Biology, Federal University of Rio Grande do Sul, Porto Alegre, Brazil.
  • Carvalho I; Institute of Mathematical and Computer Sciences, University of Sao Paulo, Sao Paulo, Brazil.
  • Schwartz IVD; Institute of Mathematical and Computer Sciences, University of Sao Paulo, Sao Paulo, Brazil.
  • Alves D; Medical Genetics Service, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.
  • Felix TM; Postgraduation Program in Genetics and Molecular Biology, Federal University of Rio Grande do Sul, Porto Alegre, Brazil.
Public Health Genomics ; 26(1): 145-158, 2023.
Article em En | MEDLINE | ID: mdl-37356424
ABSTRACT

INTRODUCTION:

The Brazilian Policy for Comprehensive Care for People with Rare Diseases (BPCCPRD) was published in 2014, accrediting several reference centers and incorporating many genetic tests for the diagnosis of rare diseases (RDs). The Brazilian Network of Rare Diseases (RARAS) comprises more than 40 institutions that offer diagnosis and treatment for RDs in Brazil. This network includes Reference Services for Rare Diseases (RDRS), Reference Services for Newborn Screening (NSRS), and University Hospitals distributed in all Brazilian regions.

OBJECTIVE:

The aim of the study was to map the availability and distribution of the BPCCPRD diagnostic procedures in the Brazilian Unified Health System through RARAS.

METHOD:

Data were collected through a questionnaire on the Research Electronic Data Capture platform, with 22 questions regarding the availability of procedures. Thirty-seven coordinators from RARAS participating centers received the questionnaire link for participation by email from August/2020 to March/2021. All participating institutions ethically approved this project.

RESULTS:

Of the 37 institutions, 23 (62.16%) offered cytogenetic tests, 20 (54.05%) offered molecular procedures, and 22 (59.46%) offered inborn errors of metabolism diagnostic tests. The Southern blot analysis, enzyme assays on cultured tissue and urinary organic acid tests had the highest outsourcing rate. On the other hand, the procedures most frequently performed on-site were bone marrow karyotype and long-term cultured karyotype. It was observed that 10 of the 37 centers (27%) did not provide access to investigated procedures (on-site or outsourced). The North and Midwest regions stood out in terms of the unavailability of such techniques in at least 40% of the evaluated institutions. DISCUSSION AND

CONCLUSION:

This study reveals large discrepancies in the supply of diagnostic procedures in the Brazilian territory. Moreover, there is a broad collaboration between services through the outsourcing of multiple diagnostic techniques to address this issue. Finally, this work corroborates the importance of mapping services for the diagnosis and treatment of individuals with RDs to propose actions for the better supply and distribution of these procedures.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Testes Genéticos / Doenças Raras Limite: Humans / Newborn País/Região como assunto: America do sul / Brasil Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Testes Genéticos / Doenças Raras Limite: Humans / Newborn País/Região como assunto: America do sul / Brasil Idioma: En Ano de publicação: 2023 Tipo de documento: Article